Jiangsu Alphamab Biopharmaceuticals
Pre-Approval PRO BETAPipeline by Phase
Therapeutic Focus
Clinical Trials (30)
A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care
Started: 3/17/2026
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
Started: 12/1/2023
JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer
Started: 1/15/2025
JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer
Started: 4/1/2026
A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Cancer
Started: 12/10/2025
Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a Phase II Clinical Study
Started: 1/17/2025
Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer
Started: 7/26/2022
KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic Carcinoma
Started: 12/2/2020
KN026 in Patients With HER2 Expressing Gastric/Gastroesophageal Junction Cancer
Started: 6/17/2019
Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid Tumors
Started: 12/7/2020
KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent
Started: 10/28/2021
KN046 in Patients With Advanced Non-small Cell Lung Cancer
Started: 5/5/2019
Efficacy and Safety Study of KN019 in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate
Started: 11/8/2019
KN046 in Subjects With Late Stage Esophageal Squamous Cell Carcinoma
Started: 6/21/2019
Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC
Started: 4/2/2025
JSKN022 in Subjects With Advanced Malignant Solid Tumors
Started: 10/23/2025
Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer
Started: 6/1/2025
To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors
Started: 4/30/2024
JSKN016HC in Patients With Advanced or Metastatic Solid Malignant Tumors
Started: 3/1/2026
A Study of JSKN027 in Patients With Advanced Solid Tumors
Started: 3/15/2026
Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors
Started: 3/15/2023
JSKN016 in Combination With D-0502 for Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer
Started: 1/1/2026
JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors
Started: 1/18/2024
JSKN033 in Chinese Subjects with Advanced Malignant Tumors
Started: 1/15/2025
Clinical Study of KN052 in Chinese Subjects With Advanced Solid Tumors
Started: 5/27/2022
Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric Cancer
Started: 9/17/2018
KN046 in Subjects With Advanced Solid Tumors and Lymphoma
Started: 12/18/2018
A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast Cancer
Started: 5/30/2019
KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular Carcinoma
Started: 6/7/2021
A Phase I Study of JSKN021 in Advanced Solid Tumors
Started: 5/31/2026